Skip to main content

Table 6 Clinical outcomes by the selected studies Melanoma and Immunotherapy

From: Oligometastasis and local ablation in the era of systemic targeted and immunotherapy

Authors (year of publication)
[reference]
Local ControlProgression free survivalOverall SurvivalToxicity
Gabani 2018 [35]N/AN/A15.4 mo (median)N.S.
Stera 2018 [36]1 yr LCR: 89.5%6 mo: 42.3%
1 yr: 25.5%
6 mo: 75.3%
1 yr: 50.8%
2 yr: 31.8%
3 > G2 (1 autoimmune hypophysitis, 1 autoimmune pancreatitis, 1 radionecrosis)a
Liniker 2016 [37]RR: 44% e 64% b  3 > G2 (1 case of radiation necrosis, 2 radiation dermatitis)
Qin 2015 [32]Ipi before RT > 6 and 12 mo response duration that Ipi after RT 19.6 mo (median)
6 mo: 95.1%
1 yr: 79.7%
Pts. Who received Ipi after radiation had fewer irAEs than those who received it before radiation
Diao 2018 [33]Non-concurrent Ipi:
1 yr, 70%
Concurrent Ipi:
1 yr, 58%
N.S.Non-concurrent Ipi:
Median,18.7 mo
1 yr, 63%
Concurrent Ipi
Median, 11.8 mo
1 yr, 50%
Acute
4 > G2 (2 cases of cerebral oedema, 2 cases of cerebral hemorrhage)c
Late
4 > G2 (Radiation Necrosis)
No G5 events
Anderson 2017 [34]93% (at the time of death)N.S.N.S.No > G3 events
1 G2 CNS bleeding
Chen 2017 [15]Non concurrent ICI:
1 yr 79%
Concurrent ICI:
1 yr 88%
N.S.Concurrent ICI: 24.7 mo
Non-Concurrent ICI: 14.5 mo
3% G3 acute CNS
No > G3 events
Chandra 2015 [38] N.S.28 mo (median)N.S.
  1. aonly attributable to SRS/SBRT+Immunotherapy
  2. b44% response rate for lesions treated sequentially, 64% for lesions treated concurrently
  3. c2/4 side effects reported in pts. who did not receive Immunotherapy